Evidence mapPaperPMID 40968430Full record

ReviewCurrent diabetes reviews2026

Severe Insulin Resistance: Diagnosis and Management.

Yu-Lan Wu, Xin Wang, Wei-Wei Zhang, Dan Feng, Xie Luo

Abstract readReview
PubMed Publisher
In one paragraph

Review in Current diabetes reviews, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Yu-Lan WuDepartment of Endocrinology, People's Hospital of Pengshui County, Pengshui, 409600, China.
Xin WangDepartment of Endocrinology, People's Hospital of Pengshui County, Pengshui, 409600, China.
Wei-Wei ZhangDepartment of Endocrinology, The Second Affiliated Hospital of Chongqing Medical University, No 74 Linjiang Road, Yuzhong District, Chongqing, 400010, China.
Dan FengDepartment of Endocrinology, People's Hospital of Pengshui County, Pengshui, 409600, China.
Xie LuoDepartment of Endocrinology, The Second Affiliated Hospital of Chongqing Medical University, No 74 Linjiang Road, Yuzhong District, Chongqing, 400010, China.

Funding

Chongqing medical scientific research project, China (Joint project of Chongqing Health Commission and Science and Technology Bureau) 2023QNXM008National Natural Science Foundation of China 81800771
6 · The paper itself

Abstract

Insulin resistance is an endocrine disorder associated with various diseases, including diabetes, metabolic syndrome, cardiovascular diseases, and cancer. However, severe insulin resistance differs significantly from common insulin resistance regarding the causes and treatment approaches. Severe insulin resistance is a group of rare disorders characterized by hyperglycemia and hyperinsulinemia, with or without hypoglycemia, along with various metabolic abnormalities and diverse clinical manifestations. Owing to their rarity and complexity, these conditions can be easily misdiagnosed as common diabetes and are often overlooked. Severe insulin resistance is typically reported in individual case studies, lacking comprehensive summaries. This article provides a detailed overview of the different types of severe insulin resistance based on the specific sites of insulin signaling defects. It includes pre-receptor signaling defects, such as insulin autoimmune syndrome, which results from insulin autoantibodies; receptor-level insulin resistance syndromes, including type A and type B insulin resistance syndromes; and post-receptor signaling defects, such as lipodystrophy syndrome. We describe the causes, clinical symptoms, diagnosis, and treatment of extreme insulin resistance and differentiate between these diseases. In this review, we aim to assist physicians in identifying the causes of severe insulin resistance early and in providing individualized treatment for patients, ultimately improving clinical outcomes.

Indexed as

Insulin ResistanceHumansHyperinsulinismInsulinLipodystrophyReceptor, InsulinSeverity of Illness IndexInsulinReceptor, Insulininsulin autoantibodiesinsulin autoimmune syndromeLipodystrophy syndromeSevere insulin resistanceType A insulin resistance syndromeType B insulin resistance syndrome

Identifiers

PMID40968430

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.